Skip directly to content

Campaign for Sofosbuvir's 5th Birthday

People living with hepatitis C, access to medicines activists, and the medical community around the world “marked” the fifth birthday of the first all-oral, one dose per day cure sofosbuvir (Sovaldi®), launched by Gilead Sciences. However, despite being a breakthrough cure, the vast majority of people still haven't been treated: a global hepatitis C coalition has released a fact sheet revealing treatment barriers that resulted in only 1.85 million of the 71 million people worldwide who need treatment, receiving Gilead’s sofosbuvir-based drugs, largely due to pricing, patents and registration delays.

Hoping to call attention to these enormous treatment barriers that still remain for most people living with hepatitis C, activists (including hepCoaltion and TAG) created resources, graphics and a social media campaign.

Read the press release

Download the Fact Sheet